Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CYP4Z1 | Q86W10 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CYP4F11 | Q9HBI6 | 1/20 | 0.38 |
| ▸ | CYP4F12 | Q9HCS2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2435272 | 0.90 | CYP4F2 (0.48) | CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL2430550 | 0.89 | CYP4F2 (0.47) | CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL2432040 | 0.88 | CYP4F2 (0.46) | CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL16030858 | 0.87 | CYP4F2 (0.53) | CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL2432833 | 0.85 | CYP4F2 (0.44) | CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL2432138 | 0.85 | CYP4F2 (0.51) | CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL2433755 | 0.83 | CYP4F2 (0.47) | CYP4F2CYP4A11ALDH1A1GAACYP4Z1 | |
| SCHEMBL12035728 | 0.81 | CA12 (0.34) | CYP4F2CYP4A11SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL16318854 | 0.79 | CYP4F2 (0.59) | CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL16048549 | 0.78 | CYP4F2 (0.47) | CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582674-B1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | CYMABAY THERAPEUTICS INC (US) | 2014-10-01 | — | — | EP | disclosed |
| US-20140121246-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8598374-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-8476308-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476308-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476308-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20130131351-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131351-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131351-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130109734-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2013-05-02 | — | — | US | disclosed |
| WO-2011159297-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| US-20110313003-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110313003-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110313003-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2011-12-22 | — | — | US | disclosed |
| EP-2367793-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | Metabolex Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20100190831-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190831-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190831-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-07-29 | — | — | US | disclosed |
| WO-2010080537-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010080537-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313003-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | CYP4F2 1483/4885CYP4A11 1325/4885ALDH1A1 3347/4885 |
| US-20100190831-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | CYP4F2 1483/4885CYP4A11 1325/4885ALDH1A1 3347/4885 |
| US-20140121246-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | CYP4F2 1483/4885CYP4A11 1325/4885ALDH1A1 3347/4885 |
| US-20130109734-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | CYP4F2 1483/4885CYP4A11 1325/4885ALDH1A1 3347/4885 |
| US-20130131351-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | CYP4F2 1483/4885CYP4A11 1325/4885ALDH1A1 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.